[
  {
    "ts": null,
    "headline": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
    "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
    "url": "https://finnhub.io/api/news?id=e8d36100f587ac0a78a0d5b73e2acd78e92612413060db07431b9027bb55dc24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764091680,
      "headline": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
      "id": 137606021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
      "url": "https://finnhub.io/api/news?id=e8d36100f587ac0a78a0d5b73e2acd78e92612413060db07431b9027bb55dc24"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline",
    "summary": "BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.",
    "url": "https://finnhub.io/api/news?id=9df7ef25c19dd422b81353c04c9b85a43368a3345f745b21997976bbfb56e89d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764085380,
      "headline": "Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline",
      "id": 137606322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.",
      "url": "https://finnhub.io/api/news?id=9df7ef25c19dd422b81353c04c9b85a43368a3345f745b21997976bbfb56e89d"
    }
  },
  {
    "ts": null,
    "headline": "Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status",
    "summary": "LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha",
    "url": "https://finnhub.io/api/news?id=e89bc01f2a32dbe7b5ab0eacac475a3d92788e6271d054e3fc798dbacfcd5a96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764073800,
      "headline": "Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status",
      "id": 137606323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha",
      "url": "https://finnhub.io/api/news?id=e89bc01f2a32dbe7b5ab0eacac475a3d92788e6271d054e3fc798dbacfcd5a96"
    }
  }
]